Provided by Tiger Trade Technology Pte. Ltd.

Defiance Daily Target 2X Long LLY ETF

24.53
-1.1300-4.40%
Post-market: 24.600.0700+0.29%19:57 EDT
Volume:421.39K
Turnover:10.77M
Market Cap:44.77M
PE:- -
High:26.91
Open:25.76
Low:24.39
Close:25.66
52wk High:31.19
52wk Low:13.93
Shares:1.83M
Float Shares:1.83M
Volume Ratio:1.94
T/O Rate:23.09%
Dividend:0.70
Dividend Rate:2.87%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

23% Weight Loss, 27% Dropouts: How Strong Is Lilly's Phase 2 Combo, Really?

Options & Short Sell
·
7 hours ago

DexCom’s Oura Bet: Potential Investment Gains Meet a Bigger Healthcare Opportunity

Bellwether Stocks Movement
·
Sep 29

The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind

Dow Jones
·
7 hours ago

Eli Lilly Says Foundayo Drug Helped Patients Lose Weight in Phase 3 Trial

Dow Jones
·
9 hours ago

Eli Lilly’s Foundayo shows cardiovascular safety in type 2 diabetes study

TIPRANKS
·
9 hours ago

Lilly's Oral Glp-1, Foundayo (Orforglipron), Demonstrated Cardiovascular Safety Alongside Sustained A1c Reduction and Weight Loss in Its Largest and Longest Type 2 Diabetes Study

THOMSON REUTERS
·
9 hours ago

Eli Lilly - Achieve-4: Foundayo Shows 16% Lower Mace-4 and 23% Lower Mace-3 Risk vs Insulin Glargine

THOMSON REUTERS
·
9 hours ago

Eli Lilly - Foundayo Shows Smaller Egrf Reduction and Greater Albuminuria Reduction vs Insulin Glargine

THOMSON REUTERS
·
9 hours ago

Sector Update: Healthcare

MT Newswires Live
·
14 hours ago

Lilly’s Clazakizumab Trial Pushes Cardiovascular Inflammation Strategy Forward

TIPRANKS
·
15 hours ago

Eli Lilly Reports 'Positive' Results From EloraTZP Trial

MT Newswires Live
·
Yesterday

Weight-Loss Drug Developers Line up to Tap Lucrative Market as Competition Heats Up

Reuters
·
Yesterday

Adding Lilly's New Drug to Zepbound Helped People Lose up to 23% of Their Weight. but There were More Side Effects.

Dow Jones
·
Yesterday

Eli Lilly Says EloraTZP Combo Delivered 'Substantial' Weight Loss, A1C Reduction in Phase 2b Trial

MT Newswires Live
·
Yesterday

Lilly says participants on EloraTZP lost up to average 23.3% of weight in study

TIPRANKS
·
Yesterday

Lilly's Eloratzp (Combination of Eloralintide and Tirzepatide) Delivered Greater Weight Loss and A1c Reduction VS. Tirzepatide 15 Mg in Adults with Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Yesterday

Eli Lilly: Plans to Initiate Phase 3 Studies of Eloratzp Co-Formulation Product by 2026 End Using Optimized Escalation Schedule

THOMSON REUTERS
·
Yesterday

Eli Lilly: at 48 Weeks, All Combinations of Eloratzp Met Primary & Secondary Endpoints

THOMSON REUTERS
·
Yesterday

Experimental Lilly Combination Drug Tops Zepbound in Weight-Loss Trial

Reuters
·
Yesterday

Eli Lilly: Participants Taking Eloratzp Lost up to Average of 54.1 Lbs (23.3%) VS. 34.4 Lbs (14.8%) with Tirzepatide 15 Mg

THOMSON REUTERS
·
Yesterday